China Cancer Drug Market will surpass US$ 30.5 Billion by the year end of 2025


Posted December 5, 2019 by PrateekRenub

According to Renub Reserach analysis China Cancer Drug Market will surpass US$ 30.5 Billion by the year end of 2025. Forecast by Drugs, Cancer & Therapy (2019 - 2025).
 
Cancer is one of the biggest burdens for so many public health departments across the world and China has even more cancer patients due to growing population at rapid pace. According to GLOBCAN, nearly 2.9 Million new cancer deaths happened in China in the year 2018. If we talk about cancer incidence, this rate is much lower in China rather than United States and United Kingdom. But when we talk about mortality rate, China mortality rate is almost 30% to 40% higher than the United States and United Kingdom. Moreover, increasing diagnostic center, improving cancer treatment therapy and acceptance of targeted drug therapy will further boost the China cancer market in forecast period. However, expensive cancer drug and various side-effects will also hinder the market. According to Renub Research Analysis, China Cancer Drug Market will surpass US$ 30.5 Billion by the year end of 2025.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-cancer-drugs-market-p.php

Renub Research report titled “China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolities, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)” provides a complete analysis of China Anti-Cancer Drugs Market.

Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=china-cancer-drugs-market-p.php

By Drugs
• Cytotoxic Drugs
o Antimetabolities
o Plant Alkaloids
o Alkylating Agents
• Targeted Drugs
• Monoclonal Antibiotics
• Hormonal Drugs
• Traditional Chinese Medicine (TCM)
• Others

By Cancer
• Lung Cancer
• Stomach Cancer
• Breast Cancer
• Esophageal Cancer
• Liver Cancer
• Others

By Therapy
• Chemotherapy
• Targeted Therapy
• Hormonal Therapy
• Others

Companies Covered in the Report
• Merck
• Celegene
• Eli Lilly
• Roche
• Sino BioPharma

If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team.

Contact Us
Email: [email protected]
Phone: +1-678-302-0700
Web: www.renub.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Renub Research
Phone 6783020700
Business Address 225 Kristie Ln
http://www.renub.com/
Country United States
Categories Biotech , Medical , Reports
Tags cancer drugs market in china , cancer drugs market size , china anticancer drugs companies , china anticancer drugs market , china cancer chemotherapy , china cancer drugs market , china cancer drugs market forecast , china cancer therapy market
Last Updated December 5, 2019